PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now looking at the association with diabetes and metabolic disease.
| less than a minute read
Checkpoint Inhibitors and Diabetes
Get in touch
Get in touch
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin. Scientists at Boston Children’s Hospital have come up with a way to thwart this wayward autoimmune reaction, and it involves a protein that plays a prominent role in new immunotherapy treatments for cancer: PD-L1.
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-10-08-10-50-28-575-67050e74c71f57809f6d0411.jpg)
Introduction Over the next 2 months, the DLA Piper Life Sciences Blog: Cortex will feature a series of articles providing an insight into...
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-11-19-12-42-49-261-673c87c925126ee9da0a18fc.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-11-05-09-46-46-710-6729e986fa0caa16109ca90f.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-11-05-09-42-20-904-A25696_Life_Sciences_Brochure_OctoberEN_Brochure_V2_FINAL_thumbnail_1.png)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-10-31-16-30-14-487-6723b096063041cc69f3284b.jpg)
